摘要
目的研究血管紧张素Ⅱ1型受体拮抗剂坎地沙坦抗大鼠肝纤维化的疗效及对血管紧张素1-7[Ang-(1-7)]的影响。方法制备四氯化碳诱导大鼠肝纤维化模型,同时应用坎地沙坦灌胃,共8周。肝组织进行常规HE与Masson三色染色,并测定门脉压及血清肝功能,血浆中Ang-(1-7)应用酶联免疫方法检测。结果与模型组大鼠比较,坎地沙坦可改善肝纤维化程度及降低门脉压,血浆Ang-(1-7)水平增加。结论坎地沙坦抗肝纤维化可能与升高Ang-(1-7)有关。
Objective To explore the protective effect of angiotensin ]I type 1 （AT1） receptor blocker candesartan in hepatic fibrosis induced by carbon tetraehloride （CCL4） in rats and effects of candesartan on Ang-（l-7）. Methods Except rats in control group, all were given intraperitoneal injections of 40% CCL4, and from the first day of the intraperitoneal injection, rats in treatment groups were given candesartan for 8 weeks by gastric garage. Liver tissue and blood samples of all rats were examined at the end of 8 weeks. Histopathologieal study of liver tissue was done with hematoxylin-eosin （HE） and Masson trichrome staining, all rats were examined portal vein pressure. Blood samples were taken for detecting alanine aminotransferase （ALT） and the levels of Ang-（1-7）evaluated by ELASA. Results Compared with the health controls, eandesartan significantly attenuated the degree of hepatic fibrosis and decreased portal vein pressure and plasma Ang-（1-7）levels increased. Conclusion Candesartan can retard the progression of hepatic fibrosis and exerts its antifibrogenic effect by adding Ang-（1-7） levels.
出处
《国际消化病杂志》
CAS
2011年第1期56-57,59,共3页
International Journal of Digestive Diseases
